JPH03224463A - Nutrient composition - Google Patents

Nutrient composition

Info

Publication number
JPH03224463A
JPH03224463A JP2324762A JP32476290A JPH03224463A JP H03224463 A JPH03224463 A JP H03224463A JP 2324762 A JP2324762 A JP 2324762A JP 32476290 A JP32476290 A JP 32476290A JP H03224463 A JPH03224463 A JP H03224463A
Authority
JP
Japan
Prior art keywords
protein
oil
nutritional composition
potato protein
fats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2324762A
Other languages
Japanese (ja)
Other versions
JP2932684B2 (en
Inventor
Ichiro Sonaka
一郎 惣中
Tetsuo Kobayashi
哲男 小林
Hiroko Futami
二見 裕子
Yoshiro Kitahara
吉朗 北原
Eiji Sukegawa
助川 英治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP2324762A priority Critical patent/JP2932684B2/en
Publication of JPH03224463A publication Critical patent/JPH03224463A/en
Application granted granted Critical
Publication of JP2932684B2 publication Critical patent/JP2932684B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE:To obtain the title composition effective for preventing and treating arteriosclerosis and thrombotic diseases, having excellent inhibitory action on rise of plasma lipid and on sthenia of blood platelet aggregation, comprising a potato protein (enzymatic hydrolyzate) and fats and oils. CONSTITUTION:The objective composition comprising preferably 10-30wt.% potato protein and/or enzymatic hydrolyzate and preferably 5-20wt.% fats and oils (preferably highly containing alpha-linolenic acid and linoleic acid as fatty acid component).

Description

【発明の詳細な説明】 産1」J■U1走証 本発明は、栄養組成物に関し、さらに詳しくはポテトタ
ンパク質またはその酵素的加水分解物にα−リノレン酸
とリノール酸を高含有する油脂を配合した栄養組成物に
関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a nutritional composition, and more specifically, to potato protein or its enzymatic hydrolyzate, fat and oil containing a high content of α-linolenic acid and linoleic acid. The present invention relates to a formulated nutritional composition.

皿来坐肢止 従来、経腸ならびに経口的に栄養補給するために使用さ
れている栄養組成物の窒素源としては、結晶アミノ酸の
他には、カゼインをはじめとする動物性タンパク賞もし
くはその酵素的加水分解物が用いられている。しかしな
がら、動物性タンパク賞とその酵素的加水分解物は、栄
養価では優れているものの、血漿脂質を上昇させる作用
が一般的に認められること(Caroll、 K、に、
 Dietaryprotein in relati
on to plasma choiesteroll
evels and atherosclerosis
、  Nutr、 Rev、 34:1−5; 197
B)から、脂質代謝改善作用という薬効的効果を意図し
た栄養組成物の窒素源としては、植物性タンパク質の中
では比較的栄養価の高い大豆タンパク質またはその酵素
的加水分解物が利用されている。上記栄養組成物の窒素
源として結晶アミノ酸を使用した際に問題となる安定性
や溶解性といった製剤学的欠点は、タンパク質の酵素的
加水分解物を用いることによって解決され、栄養学的に
も同等以上の有効性が既に特開昭64−20060号で
提案されている。臨床では、動脈硬化の一次子防の観点
から血漿脂質レベルが危険因子として重要視されている
( The Lipid Re5earch C11n
icsCoronary Primary Preve
ntion Trial Re5ults  :1、 
 Il、 JAMA%江: 351−374.1984
)。一方、脳梗塞や心筋梗塞等の血栓性疾患において血
小板機能の亢進が報告(丸山征朗:脳梗塞と血液凝固。
Nitrogen sources for nutritional compositions conventionally used for enteral and oral nutritional supplementation include crystalline amino acids, as well as animal proteins such as casein or their enzymes. hydrolyzate is used. However, although animal proteins and their enzymatic hydrolysates have excellent nutritional value, they are generally recognized to have the effect of increasing plasma lipids (Carroll, K.,
Dietary protein in relative
on to plasma choiesterroll
evel and atherosclerosis
, Nutr, Rev, 34:1-5; 197
From B), soybean protein or its enzymatic hydrolyzate, which has relatively high nutritional value among vegetable proteins, is used as a nitrogen source for nutritional compositions intended for the medicinal effect of improving lipid metabolism. . The pharmaceutical disadvantages such as stability and solubility that arise when crystalline amino acids are used as nitrogen sources in the above nutritional compositions can be solved by using enzymatic protein hydrolysates, which are nutritionally equivalent. The above effectiveness has already been proposed in Japanese Patent Laid-Open No. 64-20060. In clinical practice, plasma lipid levels are considered important as a risk factor from the perspective of primary prevention of arteriosclerosis (The Lipid Research C11n
icsCoronary Primary Preve
tion Trial Results: 1,
Il, JAMA%E: 351-374.1984
). On the other hand, it has been reported that platelet function is enhanced in thrombotic diseases such as cerebral infarction and myocardial infarction (Seiro Maruyama: Cerebral infarction and blood coagulation.

日本医師会識語、 88.352−360; 1982
)されており、これらの疾患の再発予防の薬物療法とし
て一般的にアスピリンやチクロピジン等の抗血小板薬が
用いられている(塩 栄夫:再発予防、 Pro、 M
ed。
Japanese Medical Association Knowledge, 88.352-360; 1982
), and antiplatelet drugs such as aspirin and ticlopidine are generally used as drug therapy to prevent recurrence of these diseases (Hideo Shio: Relapse Prevention, Pro, M
ed.

旦、 1109−1112; 1988)。Dan, 1109-1112; 1988).

我々は栄養素材の中で、血漿脂質の上昇抑制作用を有す
る植物性タンパク質に注目し、その血小板機能に及ぼす
作用をラットにコレステロール食を与えて検討した結果
、大豆タンパク質には血漿脂質上昇抑制作用は認められ
たが、血小板に対してはコラゲン凝集を明らかに亢進し
た。従って、大豆タンパン質は血栓の形成を助長する可
能性があり、大豆タンパク質またはその酵素的加水分解
物を含む栄養組成物に血栓性の疾患を予防する薬効的効
果は期待できない。
Among nutritional materials, we focused on vegetable protein, which has the effect of suppressing the rise in plasma lipids, and investigated its effect on platelet function by feeding rats with a cholesterol diet. However, collagen aggregation was clearly enhanced for platelets. Therefore, soy protein may promote the formation of blood clots, and a nutritional composition containing soy protein or its enzymatic hydrolyzate cannot be expected to have a medicinal effect on preventing thrombotic diseases.

本主肌■課国 本発明の課題は、優れた抗血小板作用と脂質低下作用を
有し、血栓性の疾患に対する予防および治療に有効な栄
養組成物を提供することにある。
An object of the present invention is to provide a nutritional composition that has excellent antiplatelet and lipid-lowering effects and is effective in the prevention and treatment of thrombotic diseases.

i   ゛′するための 本発明者らはかかる課題を解決すべく、種々の研究の結
果、ポテトタンパク質および/またはその酵素的加水分
解物と、−榊す油脂とを含有する組成物が、優れた抗血
小板作用と血漿脂質低下作用を有することを見いだし、
本発明を完成するに到った。
In order to solve this problem, the present inventors have conducted various studies and found that a composition containing potato protein and/or its enzymatic hydrolyzate and - Sakaki oil and fat is excellent. found that it has antiplatelet and plasma lipid-lowering effects.
The present invention has now been completed.

ポテトタンパク質およびその酵素的加水分解物は他の植
物性タンパク質と同様、血漿脂質上昇抑制作用を有して
いる上に、血小板凝集の亢進を抑制する作用をも併せも
つ有用なタンパク素材である。これと油脂を組み合わせ
ることにより、血漿脂質上昇と血小板凝集の亢進を著し
く抑制することができる。
Potato protein and its enzymatic hydrolyzate, like other vegetable proteins, are useful protein materials that not only have the effect of suppressing the increase in plasma lipids, but also the effect of suppressing the promotion of platelet aggregation. By combining this with fats and oils, increases in plasma lipids and acceleration of platelet aggregation can be significantly suppressed.

本発明で使用するポテトタンパク質はデンプン精製工程
でポテトからデンプンを取り去った後に分離、濃縮、乾
燥することにより製造されており、主として飼料用タン
パク質の原料として用いられている。ポテトタンパク質
は酵素的に加水分解することによって消化吸収性と栄養
価を高め、同時に溶解性と色と食感を改善することがで
き(特開昭64−20060号)、栄養組成物の窒素源
として利用し易くすることができる。本発明の栄養組成
物においては、ポテトタンパク質またはその酵素的加水
分解物を、単独もしくは組み合わせて使用することがで
きる。ポテトタンパク質およびその酵素的加水分解物は
、成人の蛋白質所要量を充足する点から、10〜30重
量%含有することが望ましい。
The potato protein used in the present invention is produced by removing starch from potatoes in a starch purification process, followed by separation, concentration, and drying, and is mainly used as a raw material for protein for feed. By enzymatically hydrolyzing potato protein, it can increase digestibility and nutritional value, and at the same time improve solubility, color, and texture (Japanese Patent Application Laid-Open No. 64-20060), and it can be used as a nitrogen source for nutritional compositions. It can be easily used as In the nutritional composition of the present invention, potato protein or its enzymatic hydrolyzate can be used alone or in combination. Potato protein and its enzymatic hydrolyzate are preferably contained in an amount of 10 to 30% by weight in order to satisfy the protein requirements for adults.

油脂としては、脂肪酸成分としてα−リノレン酸とリノ
ール酸を高含有する油脂が適しており、栄養組成物中に
油脂を5〜20重量%含有することが成人の栄養所要量
を充足する点からも望ましい。本発明で使用する油脂と
しては大豆油、サフラワー油、しそ油、コーン油、小麦
胚芽油、採種油、月見草油等を挙げることができる。こ
れらの油脂を単独または組み合わせて使用することがで
きる。
As the fat and oil, fats and oils that contain a high content of α-linolenic acid and linoleic acid as fatty acid components are suitable, and from the viewpoint that containing 5 to 20% by weight of fats and oils in the nutritional composition satisfies the nutritional requirements of adults. is also desirable. Examples of the oils and fats used in the present invention include soybean oil, safflower oil, perilla oil, corn oil, wheat germ oil, seed oil, and evening primrose oil. These fats and oils can be used alone or in combination.

本発明の栄養組成物は、例えば表1に示すような組成を
有する。
The nutritional composition of the present invention has a composition as shown in Table 1, for example.

表 ■ 栄養所要量と本発明の栄養組成 エネ11キー (Kcal) タンパク質(g) 油   脂軸) 糖  質(g) 250 5 (20χ) 600 4 250 5 0 13 ビタミン 八(ug**本) B+  (mg) Bz  (mg) B6  (mg) B I Z (ug) C(mg) D(ug本本本) E(mg本本*) に  (ug) ナイアシン   (B) 葉酸(mg) パントテン 酸(mg) ビオチン(ug) コリン (mg) イノシトール  (mg) 40 0.6 0.8 0 2.5 7 ・・・ O 00 ■ 1.2 2.2 0 70〜140 3 0.4 4〜7 100〜200 (mg) (1g) (mg) (ug) (mg) (mg) (mg) (mg) (mg) (爾g) (ug) 00 00 300 ・・・ 0 1.6〜3.2 5 100〜 800     750 800     750 300     375 1100〜3300 1100 1875〜5625 1875 1700〜5100 1700 10     13 2.5〜5゜02.5 2.0〜3.02 15     19 150     125 (mg) (mg) (B) (mg) 1.5〜4゜01.5 0.05〜0.2  0.05 0.05〜0.2  0,05 0.15〜0.5  0.15 「日本人の栄養所要量」 (昭和59年)生活活動強度
I:女80歳以上 Recommended dietary allow
ances(1980) :女76歳以上 lug RE=3.33 V、A、(Ill)lug 
 コレカルシフxU−ル=40  V、D、(10)l
a+g  cr−)ニア7zll−3=1.5  V、
E、(10)第四次改訂 本発明の栄養組成物は、栄養素として経口または経腸的
に、「日本人の栄養所要量」 (昭和59年)に従って
一日1回〜数回に分けて摂取される。
Table ■ Nutrient requirements and nutritional composition of the present invention Energy 11 keys (Kcal) Protein (g) Oil (fat axis) Carbohydrate (g) 250 5 (20χ) 600 4 250 5 0 13 Vitamin 8 (ug** books) B+ (mg) Bz (mg) B6 (mg) B I Z (ug) C (mg) D (ug book book) E (mg book book *) Niacin (B) Folic acid (mg) Pantothenic acid (mg) Biotin (ug) Choline (mg) Inositol (mg) 40 0.6 0.8 0 2.5 7 ... O 00 ■ 1.2 2.2 0 70-140 3 0.4 4-7 100-200 (mg) (1g) (mg) (ug) (mg) (mg) (mg) (mg) (mg) (erg) (ug) 00 00 300 ... 0 1.6-3.2 5 100 ~ 800 750 800 750 300 375 1100~3300 1100 1875~5625 1875 1700~5100 1700 10 13 2.5~5°02.5 2.0~3.02 15 19 150 125 (mg) (mg) ( B) (mg) 1.5~4゜01.5 0.05~0.2 0.05 0.05~0.2 0.05 0.15~0.5 0.15 "Nutrition requirements for Japanese people" (1981) Life activity intensity I: Female 80 years of age or older Recommended diet allowance
ances (1980): Female 76 years old or older lug RE=3.33 V, A, (Ill) lug
Cholecalcif xU-L = 40 V, D, (10)l
a+g cr-) near 7zll-3=1.5 V,
E. (10) Fourth Revision The nutritional composition of the present invention can be administered orally or enterally as nutrients, once to several times a day in accordance with the "Nutritional Requirements for Japanese People" (1981). Ingested.

本発明の栄養組成物は、優れた抗血小板作用と脂質低下
作用を併せ持つことから、動脈硬化や血栓性疾患の予防
や治療に有用であり、心筋梗塞や脳卒中の栄養補給に適
しており、中でも脳梗塞の再発予防に有用である。
Since the nutritional composition of the present invention has both excellent antiplatelet and lipid-lowering effects, it is useful for the prevention and treatment of arteriosclerosis and thrombotic diseases, and is suitable for nutritional support for myocardial infarction and stroke, among others. It is useful for preventing recurrence of cerebral infarction.

実見困 以下、実施例により本発明をより具体的に説明する。Really difficult to see Hereinafter, the present invention will be explained in more detail with reference to Examples.

実施例1 5週齢のSD系雄性ラットに0.5%コレステロール食
を供与し、8週目に鎖骨上静脈より採血し、酵素法にて
血漿コレステロール濃度を測定し、9週目に24時間絶
食の後、動脈血より調製したPRP (多血小板血漿)
を用いて血小板凝集能をアブリボメーター(NBSへマ
ドレーサー801)で測定した。実験食の組成(%)は
、タンパク質20、ミネラル混合4、ビタミン混合l、
塩化コリン0.15、セルロース2、コーン油5、コレ
ステロール0.5、コーン酸ナトリウム0.125 、
シュクロースで100に調整した。タンパク質としては
、カゼイン、大豆タンパク質、ポテトタンパク質をそれ
ぞれ使用した。コレステロールを含まないカゼイン群を
コントロールとした。
Example 1 A 0.5% cholesterol diet was fed to 5-week-old SD male rats. At the 8th week, blood was collected from the supraclavicular vein, and the plasma cholesterol concentration was measured by an enzymatic method. At the 9th week, blood was collected for 24 hours. PRP (platelet rich plasma) prepared from arterial blood after fasting
Platelet aggregation ability was measured with an alibometer (NBS Hemaderacer 801). The composition (%) of the experimental food was: protein 20, mineral mixture 4, vitamin mixture 1,
Choline chloride 0.15, cellulose 2, corn oil 5, cholesterol 0.5, sodium conate 0.125,
Adjusted to 100 with sucrose. Casein, soybean protein, and potato protein were used as proteins. A casein group containing no cholesterol was used as a control.

血漿コレステロール濃度は、カゼイン群でコントロール
に比べ有意な上昇が認められたが、植物性タンパク質で
ある大豆タンパク質、ポテトタンパク質群では血米コレ
ステロールの上昇が抑制されていた(表2)。
Although a significant increase in plasma cholesterol concentration was observed in the casein group compared to the control, the increase in blood rice cholesterol was suppressed in the soybean protein and potato protein groups, which are vegetable proteins (Table 2).

表 2  血漿コレステロール濃度 カゼイン 大豆タンパク ポテトタンパク コントロール mg/10抛β 9     138±23$ 1091±12 10      105±27 9      94±14 血小板凝集は、コラゲンを凝集惹起物質とした場合、最
大凝集率で大豆タンパク質群がコントロールの約2倍に
亢進していたのに対して、ポテトタンパク群では明らか
に凝集の亢進が抑制されていた(表3)。
Table 2 Plasma cholesterol concentration Casein Soy protein Potato protein Control mg/10 抛β 9 138 ± 23 $ 1091 ± 12 10 105 ± 27 9 94 ± 14 In the protein group, the aggregation was approximately twice as high as in the control, whereas in the potato protein group, the aggregation was clearly suppressed (Table 3).

表 3  最大凝集率(%) カゼイン    8 4±2 53±7大豆タンパク 
  9  8±9 60±6本ポテトタンパク 9 7
±6 48±15コントロール  8 6±2 32±
18実施例2 実施例1と同様に、5週齢のSD系雌雄性ラット0.5
%コレステロール食を供与し、2週毎に鎖骨下静脈より
採血して血漿コレステロール濃度を、8週目に血小板凝
集能を測定した。実験食の組成(%)は、タンパク質2
0、ミネラル混合4、ビタミン混合11塩化コリン0.
15、セルロース2、油脂5、コレステロール0.5、
コール酸ナトリウム0.125 、シュクロースで10
0に言周整した。タンパク質にカゼインを、油脂にサフ
ラワー油を配合した実験食を対照群、タンパク質にポテ
トタンパク酵素分解物を、油脂にサフラワー油を配合し
た実験食をペプチド群、タンパク質にカゼインを、油脂
に小麦胚芽油としそ油のブレンド油を配合した実験食を
ブレンド油脂、タンパク質にポテトタンパク酵素分解物
を、油脂にブレンド油を配合した実験食をペプチド+ブ
レンド油脂、対照群と同じ実験食に剖検3日前からアス
ピリン100mg/kg/dayを連設したものをアス
ピリン群とした。
Table 3 Maximum aggregation rate (%) Casein 8 4±2 53±7 Soybean protein
9 8±9 60±6 potato protein 9 7
±6 48±15 control 8 6±2 32±
18 Example 2 Same as Example 1, 5 week old male and female SD rats with 0.5
% cholesterol diet, blood was collected from the subclavian vein every two weeks to measure plasma cholesterol concentration, and platelet aggregation ability was measured at 8 weeks. The composition of the experimental food (%) is protein 2
0, mineral mixture 4, vitamin mixture 11 choline chloride 0.
15, cellulose 2, fats and oils 5, cholesterol 0.5,
Sodium cholate 0.125, sucrose 10
I adjusted my wording to 0. The experimental food containing casein as protein and safflower oil as fat was used as the control group, the experimental food containing enzymatically decomposed potato protein as protein and safflower oil as fat was used as the peptide group, the protein was casein and fat was wheat as fat. An experimental food containing a blend of germ oil and soybean oil was used as a blended oil, a protein contained potato protein enzyme decomposition product, and an experimental food containing a blend of oil and fat as peptides and blended oil was used as the control group.Autopsy 3 Those who received aspirin 100 mg/kg/day from the previous day were designated as the aspirin group.

血漿コレステロールはペプチド群、ブレンド油脂で上昇
傾向は認められたものの、対照群に比較して有意に上昇
が抑制されていた。さらに、ペプチド+ブレンド油脂で
は血漿コレステロールの上昇も認められず、ペプチドと
ブレンド油の相加効果が明かであった(図1)。血小板
凝集は、コラゲンを凝集惹起物質とした場合、最大凝集
率でペプチド群、ブレンド油脂が対照群に比較して低値
となる傾向を示したが、ペプチド+ブレンド油脂では有
意に低値となり血小板凝集抑制が認められ、その効果は
アスピリン群と同等であった。(図2)主尻生並来 以上のことから明らかなように、本発明の栄養組成物は
優れた血漿脂質の上昇抑制作用と血小板凝集の先進抑制
作用を併せもち、動豚硬化や血栓性疾患の予防や治療に
有効である。
Although plasma cholesterol tended to increase in the peptide group and blended fat and oil, the increase was significantly suppressed compared to the control group. Furthermore, no increase in plasma cholesterol was observed with the peptide + blended oil, and the additive effect of the peptide and blended oil was clear (Figure 1). Regarding platelet aggregation, when collagen was used as the aggregation-inducing substance, the maximum aggregation rate tended to be lower in the peptide group and the blended oil compared to the control group, but the value was significantly lower in the peptide + blended oil and platelet Aggregation inhibition was observed, and the effect was equivalent to that of the aspirin group. (Figure 2) As is clear from the above, the nutritional composition of the present invention has both an excellent effect of suppressing the increase in plasma lipids and an advanced suppressing effect of platelet aggregation, and is effective in preventing animal stiffness and thrombosis. It is effective in preventing and treating diseases.

【図面の簡単な説明】[Brief explanation of drawings]

図1は、実施例2におけるコレステロール上昇抑制作用
を示し、コレステロール添加量を8週間自由摂取させた
ラット(n=9〜10)の鎖骨下静脈から経通的に採血
した血漿中の総コレステロールを測定した結果である。 図2は、実施例2における血小板凝集抑制作用を示し、
コレステロール添加量を8週間自由摂取させたラフ)(
n=6〜8)の多血小板血漿を用いて、コラゲン(20
μg/raβ)による凝集を測定した結果である。
Figure 1 shows the inhibitory effect on cholesterol rise in Example 2, and shows the total cholesterol in the plasma of rats (n = 9 to 10), which were given ad libitum supplementary amounts of cholesterol for 8 weeks, and blood was collected transcutaneously from the subclavian vein. These are the measured results. FIG. 2 shows the platelet aggregation inhibitory effect in Example 2,
Ruff (Ruff) (who was given ad libitum supplementary amounts of cholesterol for 8 weeks)
Collagen (20
This is the result of measuring aggregation by μg/raβ).

Claims (6)

【特許請求の範囲】[Claims] (1)ポテトタンパク質および/またはその酵素的加水
分解物と、油脂とを含有することを特徴とする栄養組成
物。
(1) A nutritional composition characterized by containing potato protein and/or its enzymatic hydrolyzate and oil and fat.
(2)ポテトタンパク質および/またはその酵素的加水
分解物が10〜30重量%含まれている請求項1記載の
栄養組成物。
(2) The nutritional composition according to claim 1, containing 10 to 30% by weight of potato protein and/or its enzymatic hydrolyzate.
(3)油脂がその脂肪酸成分として、α−リノレン酸と
リノール酸を高含有するものである請求項1記載の栄養
組成物。
(3) The nutritional composition according to claim 1, wherein the oil or fat has a high content of α-linolenic acid and linoleic acid as its fatty acid components.
(4)油脂が5〜20重量%含まれている請求項1記載
の栄養組成物。
(4) The nutritional composition according to claim 1, which contains 5 to 20% by weight of fats and oils.
(5)経口用または経腸用である請求項1記載の栄養組
成物。
(5) The nutritional composition according to claim 1, which is for oral or enteral use.
(6)血栓性の疾患患者用である請求項1記載の栄養組
成物。
(6) The nutritional composition according to claim 1, which is for patients with thrombotic diseases.
JP2324762A 1989-12-29 1990-11-27 Nutritional composition for patients with thrombotic diseases Expired - Lifetime JP2932684B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2324762A JP2932684B2 (en) 1989-12-29 1990-11-27 Nutritional composition for patients with thrombotic diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1-342211 1989-12-29
JP34221189 1989-12-29
JP2324762A JP2932684B2 (en) 1989-12-29 1990-11-27 Nutritional composition for patients with thrombotic diseases

Publications (2)

Publication Number Publication Date
JPH03224463A true JPH03224463A (en) 1991-10-03
JP2932684B2 JP2932684B2 (en) 1999-08-09

Family

ID=26571597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2324762A Expired - Lifetime JP2932684B2 (en) 1989-12-29 1990-11-27 Nutritional composition for patients with thrombotic diseases

Country Status (1)

Country Link
JP (1) JP2932684B2 (en)

Also Published As

Publication number Publication date
JP2932684B2 (en) 1999-08-09

Similar Documents

Publication Publication Date Title
US6436431B1 (en) Fortified rice bran food product and method for promoting cardiovascular health
JP4699901B2 (en) Dietary additive with body fat metabolism function and combustion energy utilization function
CA2419026C (en) Nutritional composition and method for improving protein deposition
ES2202454T3 (en) USE OF A BALANCING AGENT FOR OMEGA-3 AND OMEGA-6 Unsaturated FATTY ACIDS.
US8388949B2 (en) Compositions comprising pantothenic acid and their use for stimulating appetite
US20080193561A1 (en) Preparation for the prevention and/or treatment of vascular disorders
CN104666290A (en) Composition for ameliorating a reduced higher brain function resulting from organic brain lesions
CA2820229A1 (en) Cardio-protective agents from kiwifruits
EP0437524B1 (en) Triglyceride and nutritional composition comprising such triglycerides.
AU2004283610B2 (en) Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging
EP3135281A1 (en) Composition for preventing or improving peripheral neuropathy
WO2000009138A1 (en) Nutritional compositions for preventing or treating hyperlipoproteinemia
KR100413940B1 (en) Preventing or improving medical symptoms caused by delayed allergic reactions
JP3173844B2 (en) Agent for increasing ω3 fatty acid in living tissue and nutritional composition containing the same
EP3630088B1 (en) Medium chain fatty acids for use in the prevention or treatment of valvular heart disease
WO2019106626A1 (en) Composition for oral administration, the use of the composition in prevention and treatment of mucositis, and a method of treatment of mucositis
JP2932684B2 (en) Nutritional composition for patients with thrombotic diseases
EP0435683A1 (en) Nutrient composition
US10285967B2 (en) Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories
AU2002320118B2 (en) Fortified ricebran food product and method for promoting cardiovascular health
JPH04279523A (en) Fatty oil processed product for stimulating immunity
JPWO2000009138A1 (en) Nutritional composition for preventing or treating hyperlipoproteinemia
JP2011046647A (en) CHOLESTEROL INHIBITOR CONTAINING POLY-gamma-GLUTAMIC ACID
Ford Essential fatty acids
AU2002320118A1 (en) Fortified ricebran food product and method for promoting cardiovascular health

Legal Events

Date Code Title Description
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090528

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090528

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090528

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100528

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100528

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110528

Year of fee payment: 12

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110528

Year of fee payment: 12